Endo Health Solutions said today it is acquiring Canadian-based specialty pharma company Paladin Labs for roughly $1.6 billion, in a stock and cash deal that expands the buyer’s global presence, ...

DUBLIN, July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals Inc.

MALVERN, Pa. — Endo Health Solutions will acquire Canadian drug maker Paladin Labs for $1.6 billion, mostly in shares of stock, Endo said Tuesday. Endo said the acquisition would accelerate its ...

MALVERN, Pa., Feb. 26, 2014 /PRNewswire/ -- Endo Health Solutions Inc. (NASDAQ: ENDP) ("Endo") today announced that, at the shareholder meeting held today, proposals related to Endo's proposed ...

Endo Health Solutions ($ENDP) needs a shot in the arm, now that its lead drug Lidoderm faces generic competition. And Endo may have found just that. The has company ...

MALVERN, Pa. (AP) -- Endo Health will spend about $1.5 billion to buy the Canadian specialty drug maker Paladin Labs, and both will then be folded into a newly-formed Irish holding company. Endo also ...

Isofol Medical has entered into a license agreement with Endo Ventures Limited, a subsidiary of Endo International (ENDP-3.8%), for the exclusive registration and commercialization of arfolitixorin in ...

MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI ® (cenobamate tablets) is now available in Canada. XCOPRI is ...

Endo Health Solutions Inc. agreed to buy Canadian specialty-pharmaceutical company Paladin Labs Inc. for about $1.6 billion, allowing Endo to continue its transition into a specialty health-care ...

(Reuters) - Endo International Plc has discussed a sale of Paladin Labs Inc, its Montreal-based specialty pharmaceutical subsidiary, to Canadian drug maker Knight Therapeutics Inc , people familiar ...